Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Corporate Breaking News

Home : Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Nov 27 2020	Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO®...


Source:https://www.prnewswire.com:443/news-releases/astellas-receives-approval-of-evrenzo-roxadustat-in-japan-for-the-treatment-of-anemia-of-chronic-kidney-disease-in-adult-patients-not-on-dialysis-301181047.html

Related News
» JinkoSolar to Report Third Quarter 2020 Results on December 7, 2020 » Lumen et Zoom combinent leurs plateformes technologiques et collaboratives pour proposer une expérience optimale